{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T07:25:02Z","timestamp":1770276302704,"version":"3.49.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:p>The aim of this study is to investigate the impact of bevacizumab intraperitoneal perfusion combined with paclitaxel and platinum-based chemotherapy on serum stromal-derived factor-1\u03b1 (SDF-1\u03b1) and chemokine ligand 5 (CXCL-5) levels in patients with ovarian cancer after tumor cell debulking surgery. This clinical study was conducted on a cohort of 89 ovarian cancer patients who underwent tumor debulking surgery at our hospital from February 2020 to February 2021. The patients were divided into two groups using a random number table: the control group (<jats:italic toggle=\"yes\">n<\/jats:italic>\u2005=\u200544) received postoperative treatment with paclitaxel and platinum-based chemotherapy, while the research group (<jats:italic toggle=\"yes\">n<\/jats:italic>\u2005=\u200545) received additional treatment with intraperitoneal perfusion of bevacizumab in addition to the control group\u2019s treatment regimen. The analysis included an assessment of the clinical efficacy of both groups, changes in tumor biomarker levels before and after treatment, serum levels of SDF-1\u03b1 and CXCL-5, T-lymphocyte subset levels, treatment-related adverse reactions, and a 2-year prognosis and survival assessment. The research group showed better performance compared to the control group in terms of disease remission rate (80.00% vs. 59.09%) and treatment effectiveness rate (95.56% vs. 75.00%) (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u20050.05). Before treatment, the levels of tumor biomarkers between the two groups were compared (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&gt;\u20050.05). After treatment, the levels of serum ferritin, carbohydrate antigen 125, carbohydrate antigen 199, and human epididymis protein 4 in both groups significantly decreased compared to before treatment, with the research group having lower levels (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u20050.05). Before treatment, serum levels of SDF-1\u03b1 and CXCL-5 between the two groups were compared (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&gt;\u20050.05). After treatment, however, the levels of SDF-1\u03b1 and CXCL-5 significantly decreased compared to before treatment, with the research group having lower levels than the control group (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u20050.05). Before treatment, there was no difference in T-lymphocyte levels between the two groups (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&gt;\u20050.05). In the control group, there was no significant change in T-lymphocyte levels before and after treatment (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&gt;\u20050.05). In the research group, however, after treatment, each indicator increased compared to before treatment, and posttreatment levels of all indicators were higher than those in the control group (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u20050.05). The adverse reactions were compared between the two groups (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&gt;\u20050.05). The research group had a longer average survival time than the control group, with 1-year and 2-year survival rates higher than the control group (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u20050.05). There was, however, no significant difference between the two groups in terms of local recurrence and metastasis (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&gt;\u20050.05). In conclusion, bevacizumab intraperitoneal perfusion combined with paclitaxel and platinum-based chemotherapy shows better clinical efficacy in the treatment of ovarian cancer after tumor cell debulking surgery. It can significantly reduce the levels of serum SDF-1\u03b1 and CXCL-5 in patients, improve survival rates, and demonstrate good safety.<\/jats:p>","DOI":"10.1097\/cad.0000000000001663","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T08:01:06Z","timestamp":1736150466000},"page":"232-237","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["The impact of bevacizumab intraperitoneal perfusion combined with paclitaxel and platinum-based chemotherapy on serum stromal-derived factor-1\u03b1 (SDF-1\u03b1) and chemokine ligand 5 (CXCL-5) levels in patients with ovarian cancer after tumor cell debulking surgery"],"prefix":"10.1097","volume":"36","author":[{"given":"Liangliang","family":"Wang","sequence":"first","affiliation":[{"name":"Oncology gynecology, The First Affiliated Hospital of Bengbu Medical University Bengbu, Anhui, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanshan","family":"Ma","sequence":"additional","affiliation":[{"name":"Oncology gynecology, The First Affiliated Hospital of Bengbu Medical University Bengbu, Anhui, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiwen","family":"Su","sequence":"additional","affiliation":[{"name":"Oncology gynecology, The First Affiliated Hospital of Bengbu Medical University Bengbu, Anhui, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dandan","family":"Nie","sequence":"additional","affiliation":[{"name":"Oncology gynecology, The First Affiliated Hospital of Bengbu Medical University Bengbu, Anhui, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihua","family":"Wang","sequence":"additional","affiliation":[{"name":"Oncology gynecology, The First Affiliated Hospital of Bengbu Medical University Bengbu, Anhui, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,1,6]]},"reference":[{"key":"R1-20250131","doi-asserted-by":"crossref","first-page":"100629","DOI":"10.1016\/j.ctarc.2022.100629","article-title":"Epithelial ovarian cancer: review article.","volume":"33","author":"Sambasivan","year":"2022","journal-title":"Cancer Treat Res Commun"},{"key":"R2-20250131","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.soncn.2019.02.001","article-title":"Ovarian cancer: an integrated review.","volume":"35","author":"Stewart","year":"2019","journal-title":"Semin Oncol Nurs"},{"key":"R3-20250131","doi-asserted-by":"crossref","first-page":"972","DOI":"10.6004\/jnccn.2022.0047","article-title":"NCCN guidelines\u00ae insights: ovarian cancer, version 3.2022.","volume":"20","author":"Armstrong","year":"2022","journal-title":"J Natl Compr Cancer Netw"},{"key":"R4-20250131","first-page":"561","article-title":"Ovarian cancer: an overview.","volume":"91","author":"Penny","year":"2020","journal-title":"Radiol Technol"},{"key":"R5-20250131","doi-asserted-by":"crossref","first-page":"47","DOI":"10.21037\/cco-20-34","article-title":"Epidemiology of ovarian cancer.","volume":"9","author":"Gaona-Luviano","year":"2020","journal-title":"Chin Clin Oncol"},{"key":"R6-20250131","first-page":"268","article-title":"Standardized diagnosis and treatment and progress of ovarian cancer.","volume":"51","author":"Cao","year":"2023","journal-title":"China J Clin"},{"key":"R7-20250131","doi-asserted-by":"crossref","first-page":"102017","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin\u00ae) in cancer treatment: a review of 15 years of clinical experience and future outlook.","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"R8-20250131","first-page":"2864","article-title":"Effects of peritoneal infusion of bevacizumab combined with paclitaxel and platinum-based chemotherapy on serum hepatocyte growth factor and macrophage migration inhibitory factor in patients with stage \u2172B-\u2173 ovarian cancer [J].","volume":"37","author":"Wang","year":"2022","journal-title":"China Mater Child Health Care"},{"key":"R9-20250131","first-page":"2975","article-title":"Application analysis of combined detection of serum SDF-1, CXCL5 and CEA in ovarian cancer.","volume":"16","author":"Zhao","year":"2019","journal-title":"Lab Med Clin"},{"key":"R10-20250131","first-page":"299","article-title":"Efficacy and safety evaluation of apatinib in the treatment of recurrent ovarian cancer.","volume":"29","author":"Chu","year":"2020","journal-title":"China J New Drug"},{"key":"R11-20250131","doi-asserted-by":"crossref","first-page":"1136596","DOI":"10.3389\/fpubh.2023.1136596","article-title":"Burden of ovarian cancer in China from 1990 to 2030: a systematic analysis and comparison with the global level.","volume":"11","author":"Wang","year":"2023","journal-title":"Front Public Health"},{"key":"R12-20250131","doi-asserted-by":"crossref","first-page":"7018","DOI":"10.1002\/cam4.2560","article-title":"Ovarian cancer: current status and strategies for improving therapeutic outcomes.","volume":"8","author":"Chandra","year":"2019","journal-title":"Cancer Med"},{"key":"R13-20250131","first-page":"2140","article-title":"Research progress on mechanism and treatment of peritoneal metastasis of epithelial ovarian cancer.","volume":"51","author":"Jin","year":"2022","journal-title":"Chongqing Med"},{"key":"R14-20250131","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1200\/JCO.21.02085","article-title":"Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer: a meta-analysis.","volume":"40","author":"Baek","year":"2022","journal-title":"J Clin Oncol"},{"key":"R15-20250131","first-page":"547","article-title":"Clinical effect of bevacizumab combined with docetaxel and gemcitabine in the treatment of recurrent platinum-resistant advanced ovarian cancer and prognosis at 1-year follow-up [J].","volume":"31","author":"Zou","year":"2019","journal-title":"Chin J Fam Plann"},{"key":"R16-20250131","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1038\/s41401-021-00803-4","article-title":"Catalpol improves impaired neurovascular unit in ischemic stroke rats via enhancing VEGF-PI3K\/AKT and VEGF-MEK1\/2\/ERK1\/2 signaling.","volume":"43","author":"Wang","year":"2022","journal-title":"Acta Pharmacol Sin"},{"key":"R17-20250131","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4103\/2311-8571.364416","article-title":"Development of intelligent acupuncture applications and related technologies.","volume":"9","author":"Bao","year":"2023","journal-title":"World J Tradit Chin Med"},{"key":"R18-20250131","doi-asserted-by":"crossref","first-page":"e161366","DOI":"10.1172\/JCI161366","article-title":"Endothelial VEGFR2-PLC\u03b3 signaling regulates vascular permeability and antitumor immunity through eNOS\/Src.","volume":"133","author":"Sj\u00f6berg","year":"2023","journal-title":"J Clin Investig"},{"key":"R19-20250131","doi-asserted-by":"crossref","first-page":"115722","DOI":"10.1016\/j.envres.2023.115722","article-title":"Doxorubicin-loaded micelles in tumor cell-specific chemotherapy.","volume":"227","author":"Almajidi","year":"2023","journal-title":"Environ Res"},{"key":"R20-20250131","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.7150\/thno.69424","article-title":"Platinum-based drugs for cancer therapy and anti-tumor strategies.","volume":"12","author":"Zhang","year":"2022","journal-title":"Theranostics"}],"container-title":["Anti-Cancer Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CAD.0000000000001663","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T11:01:18Z","timestamp":1738321278000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CAD.0000000000001663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,6]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/cad.0000000000001663","relation":{},"ISSN":["0959-4973","1473-5741"],"issn-type":[{"value":"0959-4973","type":"print"},{"value":"1473-5741","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,6]]}}}